CLYM — Climb Bio, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1768446 ·
Last close
$11.90
Market Cap
$681.43M
52W High
$14.41
52W Low
$7.91
ADV30
1,403,950
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -15,211,000 | -13,722,000 | 152,372,000 | 8,356,000 | 4,287,000 |
| Dec 2025 | 0 | — | -19,296,000 | -17,516,000 | 167,744,000 | 35,685,000 | 7,269,000 |
| Sep 2025 | 0 | — | -14,892,000 | -12,888,000 | 182,304,000 | 25,803,000 | 5,301,000 |
| Jun 2025 | 0 | — | -10,677,000 | -8,666,000 | 192,386,000 | 22,682,000 | 6,622,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-54,356,000
Investing CF
$2,833,000
Financing CF
$-21,000
CapEx
$-109,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.89
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-289,727,000
Inventory
—
Receivables
$1,366,000
ST Investments
$65,395,000
EBIT TTM
$-67,883,000
Pretax Income TTM
$-59,851,000
Interest Exp TTM
—
Analysts
12
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -67,883,000 | -59,851,000 | 167,744,000 | 7,269,000 | — | -54,356,000 |
| Dec 2024 | 0 | -30,361,000 | -73,897,000 | 217,187,000 | 5,306,000 | — | -15,562,000 |
| Dec 2023 | 0 | -40,275,000 | -35,119,000 | 110,469,000 | 2,870,000 | — | -20,599,000 |
| Dec 2022 | 0 | -45,135,000 | -45,244,000 | 134,992,000 | 6,277,000 | — | -37,369,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.13
Max Pain — expiry 2026-10-16
max pain strike: $7.50 · spot: $11.90 · call oi: 3,787 · put oi: 8Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RIGL | RIGEL PHARMACEUTICALS INC | $681.06M | $36.81 | — |
| OCS | Oculis Holding AG | $682.99M | $11.31 | — |
| EVO | Evotec SE | $678.79M | $1.91 | — |
| NVCT | Nuvectis Pharma, Inc. | $678.43M | $21.52 | — |
| STTK | Shattuck Labs, Inc. | $675.24M | $7.07 | — |
News headlines (Yahoo Finance, 1h cache)
Is Artiva Biotherapeutics, Inc. (ARTV) Outperforming Other Medical Stocks This Year?
2026-07-08 13:40 · Yahoo
Climb Bio Announces Initial Phase 1b Data Demonstrating On-Target Clinical Activity for Budoprutug in Immune Thrombocytopenia at EHA Congress 2026
2026-06-11 11:00 · Yahoo
Climb Bio Presents CLYM116 Initial Phase 1 Safety Data and Translational Modeling Results at European Renal Association (ERA) Congress 2026 Supporting Continued Development
2026-06-05 11:00 · Yahoo
Climb Bio to Present on CLYM116 and Budoprutug Programs at European Renal Association (ERA) Congress 2026
2026-05-26 11:00 · Yahoo
Climb Bio Teases Key Budoprutug, CLYM116 Readouts at BioConnect
2026-05-21 05:02 · Yahoo
Climb Bio to Present New Budoprutug Clinical Data at European Hematology Association (EHA) 2026 Congress
2026-05-14 11:00 · Yahoo
Climb Bio to Present at Upcoming Investor Conferences
2026-05-12 11:00 · Yahoo
Climb Bio Reports First Quarter 2026 Financial Results and Provides Business Updates
2026-05-07 11:00 · Yahoo
Climb Bio Spotlights Budoprutug CD19 Strategy, Sets Up 2026 Data Readouts in pMN, ITP and SLE
2026-05-05 19:27 · Yahoo
Climb Bio (CLYM) Enters Agreement for $110M Private Placement Financing
2026-05-05 17:05 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.